Tenaya Desnuda Galería de Fotos y Vídeos

Tenaya Therapeutics to Announce New Interim Data from MyPEAK™-1 Phase 1b/2 Trial of TN-201 for Adults with MYBPC3-Associated HCM on Wednesday, June 3, 2026

Tenaya Therapeutics Announces Interim Data from MyPEAK™-1 Showing Treatment of MYBPC3-associated HCM with TN-201 Gene Therapy Resulted in Consistent Signs of Cardiac ...

Tenaya Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update

Tenaya Therapeutics Announces Proposed Public Offering

Tenaya Therapeutics to Participate in the Jefferies Global Healthcare Conference 2026

Tenaya Therapeutics to Present Five Abstracts on Innovative Heart Disease Gene Therapies at ASGCT 2025 Annual Meeting

Tenaya Therapeutics to Present Preclinical Data on Gene Therapy Programs and Platform Capabilities at the American Society of Gene and Cell Therapy 25th Annual Meeting

Tenaya Therapeutics Reports Promising Early Data from MyPEAK™-1 Phase 1b/2 Clinical Trial of TN-201 for Treatment of MYBPC3-Associated Hypertrophic Cardiomyopathy

Tenaya Highlights Growing Capabilities in AAV Manufacturing, Capsid Engineering and Expansion into Gene Editing with Six Abstracts Accepted for Presentation at the ASGCT 26th ...

Tenaya Therapeutics Publishes Preclinical Data Demonstrating TN-201 Enhances Cardiac Function and Survival in MYBPC3 Cardiomyopathy Models

Tenaya Therapeutics Announces Late-Breaking Oral Presentation of New Clinical Data from RIDGE™-1 Phase 1b/2 Clinical Trial of TN-401 Gene Therapy in Adults with PKP2 ...

Tenaya Therapeutics Stock Jumps After New Alnylam Deal

Analysts Are Bullish on Top Healthcare Stocks: Ligand Pharma (LGND), Tenaya Therapeutics (TNYA)

Tenaya Therapeutics Shareholders Approve Expanded Equity Incentive Plan

Tenaya Therapeutics, Inc. (TNYA) Reports Q1 Loss, Misses Revenue Estimates

Tenaya tackles genetic heart condition after thorough screening process nails down target

Tenaya gene therapy for deadly heart condition boosts long-term survival in mice

Why Tenaya Therapeutics, Inc.’s (TNYA) Stock Is Down 9.02%

Tenaya Therapeutics (TNYA) Is Up 26.6% After TN-401 Data Buzz and Narrower Losses Has The Bull Case Changed?

Tenaya, Alnylam in Cardiovascular Disease Research Collaboration Worth Up to $1.14B

Tenaya Therapeutics' gene therapy data highlights early heart rhythm improvements

Alnylam’s research pact worth up to $1.1B sends Tenaya higher

Positive Interim Data from Cohorts 1 and 2 of Tenaya’s RIDGE™-1 Phase 1b/2 Clinical Trial of TN-401 Demonstrated Consistent Reductions in Arrhythmia Burden for Adults with ...

Tenaya Therapeutics Presents Promising Interim Clinical Data from MYPEAK™-1 Phase 1b/2a Clinical Trial of TN-201 Gene Therapy for the Treatment of MYBPC3-Associated ...

Tenaya Therapeutics to Announce Initial Data from MyPEAK-1 Phase 1b/2 Clinical Trial of TN-201 Gene Therapy for MYBPC3-Associated Hypertrophic Cardiomyopathy on Tuesday ...

Tenaya Therapeutics to Present Preclinical Data on TN-401 PKP2 Gene Therapy Program at Heart Rhythm 2022

Tenaya Therapeutics Announces Publication of Preclinical HDAC6 Inhibitor Data for Heart Failure with Preserved Ejection Fraction in Nature Communications

Canaccord Genuity Sticks to Their Buy Rating for Tenaya Therapeutics (TNYA)

Tenaya Therapeutics stock hits 52-week low at $0.68 amid market challenges

Tenaya Therapeutics stock hits 52-week low at $1.49